UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial

Annals of oncology, 2014-02, Vol.25 (2), p.429-434

2014

Volltextzugriff (PDF)

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours

European journal of cancer (1990), 2006, Vol.42 (1), p.50-54

2006

Volltextzugriff (PDF)

Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy

Annals of oncology, 2013-04, Vol.24 (4), p.1017-1025

2013

Volltextzugriff (PDF)

Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924

Journal of clinical oncology, 2001-05, Vol.19 (10), p.2638-2646

2001

Volltextzugriff (PDF)

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy

Annals of oncology, 2017-11, Vol.28 (11), p.2741-2746

2017

Volltextzugriff (PDF)

Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial

European journal of cancer (1990), 2012-02, Vol.48 (3), p.311-323

2012

Volltextzugriff (PDF)

Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer

Oncology, 2005-01, Vol.68 (1), p.2-9

2005

Volltextzugriff (PDF)

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Annals of oncology, 2019-06, Vol.30 (6), p.970-976

2019

Volltextzugriff (PDF)

Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer

Annals of oncology, 2008-09, Vol.19 (suppl-7), p.vii91-vii95

Sternberg, C. N.

2008

Volltextzugriff (PDF)

Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies

JNCI : Journal of the National Cancer Institute, 2012-01, Vol.104 (2), p.93-113

2012

Volltextzugriff (PDF)

Assessing the impact of evolving evidence in renal cell carcinoma treatment: An update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT)

European journal of cancer (1990), 2014-12, Vol.50 (18), p.3153-3160

2014

Volltextzugriff (PDF)

Evaluation of treatment options for patients with advanced renal cell carcinoma: Assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology

European journal of cancer (1990), 2012-05, Vol.48 (7), p.1038-1047

2012

Volltextzugriff (PDF)

The global landscape of drug development for kidney cancer

Cancer treatment reviews, 2020-09, Vol.89, p.102061-102061, Article 102061

2020

Volltextzugriff (PDF)

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

Annals of oncology, 2018-02, Vol.29 (2), p.361-369

2018

Volltextzugriff (PDF)

Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL

Annals of oncology, 2016-02, Vol.27 (2), p.286-294

2016

Volltextzugriff (PDF)

Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer

Annals of oncology, 2018-11, Vol.29 (11), p.2200-2207

2018

Volltextzugriff (PDF)

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes

Annals of oncology, 2024-04, Vol.35 (4), p.392-401

2024

Volltextzugriff (PDF)

Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial

Annals of oncology, 2021-06, Vol.32 (6), p.726-735

2021

Volltextzugriff (PDF)

Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy

Annals of oncology, 2016-03, Vol.27 (3), p.545-546

2016

Volltextzugriff (PDF)

What's new in the treatment of advanced prostate cancer?

European journal of cancer (1990), 2003, Vol.39 (2), p.136-146

Sternberg, C.N.

2003

Volltextzugriff (PDF)

Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study

Annals of oncology, 2009-06, Vol.20 (6), p.1062-1067

2009

Volltextzugriff (PDF)

Clinical and Molecular Determinants of Survival in Pancreatic Cancer Patients Treated with Second-line Chemotherapy: Results of an Italian/Swiss Multicenter Survey

Anticancer research, 2010-10, Vol.30 (10), p.4289-4295

2010

Volltextzugriff (PDF)

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL

Prostate cancer and prostatic diseases, 2017-06, Vol.20 (2), p.221-227

2017

Volltextzugriff (PDF)

Novel hormonal therapy for castration-resistant prostate cancer

Annals of oncology, 2012-09, Vol.23 Suppl 10, p.x259-x263

Sternberg, C N

2012

Volltextzugriff (PDF)

1 – 25 von 948

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(758)
Mit Volltextzugriff
(805)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(424)
Life Sciences & Biomedicine
(346)
Humans
(310)
Male
(196)
Biological And Medical Sciences
(167)
Medical Sciences
(145)
Female
(139)
Oncology
(137)
Aged
(120)
Middle Aged
(114)
Adult
(86)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(63)
Pharmacology. Drug Treatments
(62)
Chemotherapy
(60)
Aged, 80 And Over
(55)
Physical Sciences
(55)
Animals
(53)
Antineoplastic Agents
(50)
Urinary Bladder Neoplasms - Drug Therapy
(49)
Urology & Nephrology
(48)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours

Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy

Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial

Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer

Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies

Assessing the impact of evolving evidence in renal cell carcinoma treatment: An update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT)

Evaluation of treatment options for patients with advanced renal cell carcinoma: Assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology

The global landscape of drug development for kidney cancer

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL

Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial

Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy

What's new in the treatment of advanced prostate cancer?

Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study

Clinical and Molecular Determinants of Survival in Pancreatic Cancer Patients Treated with Second-line Chemotherapy: Results of an Italian/Swiss Multicenter Survey

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL

Novel hormonal therapy for castration-resistant prostate cancer

Suchergebnisse filtern